Manipal Health Enterprises has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI), marking a significant step towards its initial public offering. The company, part of the Manipal Group, operates in the healthcare sector. This filing provides investors with preliminary details regarding the issue size, price band, and key financial metrics.

Company Overview

Manipal Health Enterprises is engaged in the healthcare sector. As part of the broader Manipal Group, the company leverages established brand equity and operational infrastructure. The IPO aims to raise capital for business expansion and strengthening its market position in the healthcare industry.

Offer Details

The company has defined the following parameters for its IPO:

• Price Band: ₹560 to ₹590 per share
• Issue Size: Minimum ₹14,000 crore to Maximum ₹5,00,000 crore
• Minimum Bid Quantity: 25 shares

The objects of the issue and specific timeline for the opening and closing dates will be detailed further as the process advances. Investors are advised to monitor official announcements for updates on the subscription window.

Financial Highlights

Specific financial data such as revenue trends, profit margins, and key ratios were not provided in the current data set. Detailed financial performance metrics will be available in the final prospectus.

Risk Factors

Potential risks associated with the investment include regulatory changes in the healthcare sector, competition from established players, and operational challenges. Specific material risks will be outlined in the final DRHP document.

Valuation & Peer Comparison

Valuation metrics relative to peers are not yet available as the financial data is sparse. A comprehensive peer comparison will be possible once detailed financials and the final issue size are confirmed.

Bottom Line

The filing of the DRHP by Manipal Health Enterprises indicates its readiness to enter the public markets. With a price band of ₹560-₹590 and a substantial issue size range, the IPO attracts attention. Investors should wait for complete financial disclosures before making any decisions.

Manipal Health Enterprises (CIN: U85110KA2010PLC052540), India's largest pan-India multispecialty hospital network by licensed bed capacity, has filed its Draft Red Herring Prospectus (DRHP) with SEBI. The company, which operates 49 hospitals with 13,037 licensed beds across 14 states and union territories, is preparing for an Initial Public Offering scheduled to open on 29-Jul-2026. This move marks a significant step for the healthcare giant, which serves 6.30 million patients annually and is backed by marquee institutional investors including Temasek Holdings, TPG SG Magazine, and Novo Holdings.

Company Overview

Manipal Health Enterprises is the second-largest hospital chain in India by number of hospitals and the only private hospital chain with a leadership position in three major metros: Bengaluru, Kolkata, and Pune. The company's clinical strategy is anchored around six high-acuity specialties known as CONGO-R (Cardiac Sciences, Oncology, Neurosciences, Gastro Sciences, Orthopaedics, and Renal Sciences).

As of 31-Mar-2026, the company operated:

• 49 hospitals across 14 states and union territories
• 13,037 licensed beds, with ~46.78% located in metro cities
• A workforce of 11,064 doctors, 11,048 nurses, and 6,362 paramedics

The company has been a leading consolidator in the sector, acquiring 5,548 beds through M&A between 31-Mar-2021 and 31-Mar-2026. It also boasts advanced infrastructure, including 18 soft tissue robots, 23 orthopedic and spine surgical robots, and 19 LINACs.

Offer Details

The IPO is scheduled to open on 29-Jul-2026 and close on 31-Jul-2026. The allotment date is set for 03-Aug-2026, with listing expected on 05-Aug-2026. As of the latest DRHP filing, the price band, face value, lot size, and total issue size (Fresh Issue + OFS) have not been disclosed.

Objects of the Issue

The company has outlined specific uses for the net proceeds from the issue:

Financial Highlights

Manipal Health Enterprises has demonstrated strong revenue growth over the past two years. Revenue from operations grew at a CAGR of 29.41% from ₹6,171.63 Crore in FY2024 to ₹10,335.75 Crore in FY2026. However, Profit After Tax (PAT) declined by 15.27% YoY in FY2026 to ₹916.52 Crore, despite the revenue surge.

The company achieved a negative working capital cycle of 13 days in FY2026, reflecting strong operational efficiency. However, total assets nearly doubled to ₹24,864.50 Crore in FY2026, driven by acquisitions, leading to a decline in Return on Equity (ROE) to 10.42% from 18.03% in FY2025.

Risk Factors

Investors should consider the following material risks disclosed in the DRHP:

1. Geographic Concentration: Karnataka contributed 46.40% of revenue from operations in FY2026, down from 59.98% in FY2024. Disruptions in this state could materially impact performance.
2. High Indebtedness: Outstanding borrowings stood at ₹11,185.024 Crore as of 31-May-2026, with 45.25% subject to variable interest rates. This exposes the company to interest rate fluctuations.
3. Occupancy Rates: Occupancy rates have remained flat at 64.45% in FY2026 and 64.47% in FY2025, suggesting limited headroom for organic growth without capacity expansion.
4. Regulatory Approvals: As of the Red Herring Prospectus date, 39 material approvals were pending. Failure to obtain these could lead to operational restrictions.
5. Acquisition Integration: The company has recorded impairments in the past, including ₹114.065 Crore for HealthMap Diagnostics in FY2024. Future integration risks remain.

Valuation & Peer Comparison

Specific peer comparison data and valuation multiples (P/E, P/B) are not available as the price band has not been disclosed. However, the company's revenue CAGR of 29.41% positions it as a high-growth player in the Indian healthcare sector. The significant debt reduction planned via the IPO (₹5,552.76 Crore) is expected to improve future profitability through interest savings.

Bottom Line

Manipal Health Enterprises presents a compelling growth story with India's largest multispecialty hospital network and strong institutional backing. The IPO offers a clear path to deleveraging, which should boost future PAT. However, investors must weigh this against the recent decline in PAT, high debt levels, and geographic concentration risks. With the IPO opening on 29-Jul-2026, market participants will need to wait for the price band disclosure to assess valuation adequacy.